-
Mashup Score: 5
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Home - 11 day(s) ago
Activity Overview
Source: na.eventscloud.comCategories: General Medicine News, Oncologists1Tweet-
🔬 Explore the latest on BCMA-directed therapies for MM! Gain confidence in managing treatment strategies & optimizing patient care with emerging data. 📢 Learn more: https://t.co/665mPZNthJ and Join 👉 @KirollosPharmD, @VictoriaNachar, @jayinabox #MultipleMyeloma… https://t.co/lUVoWn9o8M https://t.co/krNhG8791H
-
-
Mashup Score: 2
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
Teclistamab combined with daratumumab demonstrated manageable safety, unprecedented efficacy, and successful stem cell mobilization in transplant-eligible, newly diagnosed #MultipleMyeloma patients. https://t.co/970eTsgVmW https://t.co/rMhRs4OWlH
-
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
The CEPHEUS trial has established D-VRd as a new standard of care for transplant-ineligible and transplant deferred patients with newly diagnosed #MultipleMyeloma. Keep reading: https://t.co/GzfR6wzRJJ https://t.co/yWyABDuu3Z
-
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
In patients with high-risk smoldering #multiplemyeloma, subcutaneous daratumumab monotherapy resulted in improved overall survival compared to active monitoring. Keep reading: https://t.co/PQsAutajgX https://t.co/FWwC2vt4vB
-
-
Mashup Score: 0
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Jeffrey V. Matous, MD, shares insights from hashtag#ASH2024, discussing how telehealth and innovative care models can help overcome barriers to expanding bispecific antibody therapies in community health care. Watch now: https://t.co/Wbd3aUGqLf #MultipleMyeloma
-
-
Mashup Score: 0Excess BMI May Increase Risk of Progression From MGUS to MM - 1 month(s) ago
Being obese at the time of MGUS diagnosis was associated with a 27% increase in the risk of progression to MM.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Having a BMI in the normal range at diagnosis and maintaining a normal BMI over time may prevent progression from MGUS to #multipleMyeloma. Published in @JAMANetworkOpen. https://t.co/wuEE5JhuuG
-
-
Mashup Score: 0
The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Patients with #multiplemyeloma have a greater likelihood of long-term survival if they are younger and healthier at the time of their diagnosis, according to new research: https://t.co/rfD8TQn6Bu https://t.co/iU0qQ13Dwj
-
-
Mashup Score: 0Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond - 2 month(s) ago
Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Advancing myeloma care: Saad Usmani, MD, MBA, FACP, FASCO, discusses the IFM2017-03 trial and the future of research. Stay ahead: https://t.co/bpOECYi4Cq #MultipleMyeloma
-
-
Mashup Score: 4MRD Status Important Prognostic Factor for R/R MM Treated With T-Cell Redirecting Therapies | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Measurable residual disease (MRD)-negative complete response (CR) was the most relevant prognostic factor identified among patients with relapsed or refractory multiple myeloma (R/R MM) treated with T-cell redirecting immunotherapy, according to the results of a study published in the American Journal of Hematology. “Undetectable MRD is frequently considered a treatment endpoint, and there is increasing interest in using it for
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
A study published in the American Journal of Hematology analyzes the impact of complete remission and measurable residual disease in relapsed/refractory #MultipleMyeloma patients treated with T-cell redirecting immunotherapy. More here: https://t.co/5GKX8ljdfO @ASHClinicalNews https://t.co/Km7mnxR7Ay
-
The CEPHEUS trial has established D-VRd as a new standard of care for transplant-ineligible and transplant deferred patients with newly diagnosed #MultipleMyeloma. Keep reading: https://t.co/GzfR6wzRJJ https://t.co/yWyABDuu3Z